Piperazine erastin is an analog of erastin which induces an iron-dependent form of non-apoptotic cell death, termed ferroptosis.
Erastin is a ferroptosis activator. It triggers a unique iron-dependent form of non-apoptotic cell death that is termed as ferroptosis. Piperazine erastin is a more effective analog of erastin which is more water-soluble (0.086 mM for erastin versus 1.4 mM for piperazine erastin) and more metabolically stable. Piperazine erastin is affected similarly by cell death modulators as erastin and displays a distinct pattern from other non-FIN lethal compounds[1].
In the xenograft mouse model, a significant delay in tumor growth is observed in the piperazine erastin-treated group compared to the vehicle-treated group. Ptgs2 is upregulated in mouse liver with 10 or 60 mg/kg piperazine erastin administration[1].
[1]. Yang WS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014 Jan 16;156(1-2):317-331.